# Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con

> The next catalyst for menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa), sponsored by Sanofi (SNY), is its topline data readout, Mar to Jun 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) |
| Codes |  |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | Meningococcal Infection |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Meningococcal Infection; Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07710872 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07710872

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Meningococcal Infection; Healthy Volunteers.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07710872 (Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in China): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-13 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT07710872

## Same indication

- [Menacyw conjugate vaccine](https://sec-api.dev/pdufa/menacyw-conjugate-vaccine) (SNY)

Calendar months: [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con

```bibtex
@misc{secapidev_pdufa_menquadfi_meningococcal_polysaccharide_serogroups_a_c_w_and_y_tetanus_toxoid_con_20261116,
  title        = {Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_menquadfi_meningococcal_polysaccharide_serogroups_a_c_w_and_y_tetanus_toxoid_con_20261116","title":"Menquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/menquadfi-meningococcal-polysaccharide-serogroups-a-c-w-and-y-tetanus-toxoid-con","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
